Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{186941,
        author = {Dr. Koyel Misra and Dr. Subhajit Mukherjee},
        title = {From Innovation to Impact: The Clinical and Human Dimensions of Modern Chemotherapy},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {6},
        pages = {3381-3387},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=186941},
        abstract = {The advent of second- and third-generation chemotherapeutic agents has significantly transformed cancer treatment, offering improvements in therapeutic outcomes, patient tolerability, and compatibility with targeted and combination therapies. Compared to first-generation drugs, these newer agents deliver enhanced efficacy and reduced systemic toxicity, though they also introduce complex challenges such as resistance, cumulative toxicity, and economic burden. This review critically evaluates the clinical performance, side effect profiles, and life quality trade-offs associated with second- and third-generation chemotherapies. It further discusses their broader social, economic, and ethical implications, highlighting the need for personalized approaches, policy considerations, and future innovations to ensure the sustainable advancement of chemotherapy.},
        keywords = {Second-generation chemotherapy, Third-generation agents, Cancer pharmacology, Drug resistance, Chemotherapy toxicity, Quality of life, Targeted therapy, Combination regimens, Oncology ethics, Health disparities, Precision medicine},
        month = {November},
        }